AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 12 min read$KZIA

Kazia Reports Paxalisib Data In Immunotherapy-Resistant Colorectal Cancer

Kazia Therapeutics (KZIA) reported preclinical data showing its lead asset, paxalisib, reduced tumor burden in immunotherapy-resistant colorectal cancer by 52% as a monotherapy and by an additional 50% when combined with Pembrolizumab. The treatment was well tolerated, and the company plans to advance paxalisib into a Phase 2 clinical study. KZIA's stock closed at $13.77, up 1.40%, and was at $13.90 in pre-market trading.

Original reporting
rttnews.com
Published Sep 1, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 6:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$KZIA
Bullish
high confidence
Mentioned
$KZIA
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$KZIABullishMed
01

Why it matters

The disclosed preclinical efficacy and Phase 2 plan could catalyze a short‑term rally, but long‑term value depends on Phase 2 outcomes.

02

Market read

First report of promising preclinical data for a hard‑to‑treat cancer subtype; likely to move KZIA stock and influence peer valuations.

03

What to watch

Upcoming regulatory pathway, competition from other PI3K inhibitors, and the need for clear biomarker strategy.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Kazia Therapeutics is a clinical‑stage biotech focused on oncology, recently trading between $4.86 and $17.40.

Company-level read

Ticker impact

$KZIABullishHigh confidence
Context

Kazia Therapeutics disclosed preclinical paxalisib data showing 52% tumor reduction and enhanced effect with pembrolizumab, and announced a Phase 2 plan.

Expected impact

Potential upside of 5‑10% in the near term if investors view the data as a meaningful milestone.

Evidence & confidence

First disclosure of efficacy data for a high‑need indication; biotech stocks typically react strongly to early‑stage trial news.

Market effects

Sector

May increase interest in MSS/pMMR colorectal cancer programs and boost related biotech peers.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Highlights a potential new therapeutic approach for immunotherapy‑resistant cancers, relevant to global oncology research.

Counterpoint

What could challenge this read

Preclinical data may not translate to clinical success; investors should weigh the high failure risk of early‑stage oncology programs.

Key entities

  • Company
    Kazia Therapeutics Limited

    Biotech developer of paxalisib for colorectal cancer.

  • Drug
    Pembrolizumab

    Checkpoint inhibitor used in combination with paxalisib in the study.

Read at source← All news

Also covered by

1 outlet

Related articles

SEP 22
$KZIAMedAI 8/10

Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders

Kazia Therapeutics (KZIA) announced that Sovargen Co. dosed the first patient in a Phase 1b/2a trial of paxalisib for rare seizure disorders. The milestone triggers a $2 million payment to Kazia, with potential for up to $17 million more. Paxalisib is being developed for intractable epilepsy associated with FCD T2 and TSC, with Kazia retaining oncology focus.

prnewswire.com2 min
SEP 9
$KZIALowAI 8/10

Kazia Therapeutics Announces First Patient Dosed in PNOC035 Clinical Study Evaluating Paxalisib for Recurrent Pediatric AT/RT Brain Cancer

Kazia Therapeutics (NASDAQ: KZIA) announced the first patient has been dosed in a Phase 2 study (PNOC035) evaluating paxalisib plus gemcitabine for recurrent pediatric AT/RT brain cancer. The study, conducted by the Pediatric Neuro-Oncology Consortium, aims to address a condition with no approved therapies. Preclinical data showed a significant survival increase, supporting the trial's rationale. Paxalisib has received FDA orphan drug and rare pediatric disease designations for AT/RT.

prnewswire.com2 min
SEP 1
$KZIALow

Kazia advances paxalisib colorectal cancer program

Kazia Therapeutics (KZIA) reported paxalisib reduced tumor burden by 52% in a colorectal cancer model. The company plans a Phase 2 trial in 2027, evaluating paxalisib alone and with immunotherapy. Kazia is developing biomarkers and has filed a patent for colorectal cancer applications.

grafa.com1 min
SEP 1
$KZIAMedAI 8/10

Kazia expands paxalisib breast cancer trial program

Kazia Therapeutics reported preclinical data showing paxalisib's activity in HR+/HER2- breast cancer models. The company will expand its clinical trial to evaluate paxalisib combinations in metastatic breast cancer, with patient enrollment expected to begin before the end of 2026. Kazia filed a provisional patent related to the program and expects full enrollment by the end of 2027, with a complete data readout in 2028.

grafa.com1 min
SEP 1
$KZIAMedAI 8/10

BTIG raises Kazia Therapeutics stock price target on trial data

BTIG raised its price target for Kazia Therapeutics (NASDAQ:KZIA) to $40 from $34, citing positive trial data for paxalisib in metastatic triple-negative breast cancer. The stock has surged nearly 100% year-to-date to $12.71. Kazia also announced a $40 million public offering. BTIG noted the data showed an 83% overall response rate and no serious adverse events.

investing.com2 min